CRISPR editing inside the body slashes the protein behind ATTR amyloidosis

Published · Researched 2026-09-22

What happened (dated facts)

NTLA-2001, an in-vivo CRISPR-based therapy for transthyretin (ATTR) amyloidosis, produced striking early results: a single infusion drove roughly 87–93% mean reductions in the disease-causing TTR protein in higher-dose cohorts. In a 2024 report on the cardiomyopathy population, 92% of treated patients maintained or improved their NYHA heart-failure class, with average one-year TTR reduction of about 90%. ATTR amyloidosis — in which misfolded TTR protein builds up in the heart and nerves — is progressive and fatal without treatment. The therapy remains investigational and early-stage.

Why it is genuinely positive

This is CRISPR editing performed directly inside a living person's body, switching off the production of a toxic protein with a single infusion — and the reductions (~90%) are among the deepest ever reported for a gene-editing therapy, accompanied by maintained or improved cardiac function. It is a landmark proof that in-vivo genome editing can work at clinical scale.

Social pulse

On Threads (searched 2026-09-22), NTLA-2001 is being tracked by the science community: @nonproscience posted a detailed Chinese-language update on Intellia's NTLA-2001 for hereditary transthyretin amyloidosis, noting Phase 3 enrollment had begun and citing the Phase 1 finding that the lowest-dose group saw blood TTR reduced by an average of 52% at 28 days. The therapy is in genuine community discussion among science followers.

Verified quotes

None captured.

Verification

• Tier: 2
• Primary source: Inside Precision Medicine report on the first positive in-vivo CRISPR data in humans (https://www.insideprecisionmedicine.com/news-and-features/first-positive-data-of-in-vivo-crispr-based-genome-editing-in-humans-reported/). Proves: ~87–93% mean TTR reduction in higher-dose cohorts; 92% maintained/improved NYHA class; ~90% average 1-year TTR reduction.
• Social sources: Threads — @nonproscience (detailed community post tracking NTLA-2001's Phase 1 results and Phase 3 enrollment). Proves: the therapy is in genuine discussion among science followers.
• Positivity check: measured deep protein knockdown with functional cardiac outcomes — genuine, with investigational/early-stage status stated.

Key facts

UNVERIFIED points

• Social-layer posts about NTLA-2001 were not yet observed; tier cannot be finalized until they are.

Sources

• Primary source: Inside Precision Medicine report on the first positive in-vivo CRISPR data in humans ( — retrieval date not recorded